Navigation Links
Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis
Date:7/5/2009

EMERYVILLE, Calif. and HUENENBERG, Switzerland, July 5 /PRNewswire-FirstCall/ -- Alcon, Inc. (NYSE: ACL) and its partner, NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY), announced today that Alcon has begun treating patients in a Phase 2 clinical trial of NovaBay's patented lead Aganocide(R) compound, NVC-422, for viral conjunctivitis, a type of "pink eye". Conjunctivitis is a pervasive and painful condition that affects both adults and children, leading to more than four million doctor and emergency room visits in the United States each year.

NovaBay has a licensing and research collaboration agreement with Alcon, the world's leading eye care company, for use of its Aganocide(R) compounds in the eye, ear and sinus, and in contact lens solutions.

Developed by NovaBay to mimic the body's defense against infection, Aganocides(R) are proprietary synthetic analogs of the same molecules used by white blood cells to destroy harmful microbes in the body, such as viruses and bacteria. Because of their natural mechanism of action, NovaBay believes that Aganocide(R) compounds have a low potential for generating microbial resistance, offering a potential solution to the problem of rising resistance of microbes to traditional antibiotics.

The Phase 2 viral conjunctivitis study follows a recently completed Phase 1 trial in which safety and tolerability were successfully demonstrated in 120 healthy volunteers with no reported serious adverse events.

"We are pleased to be entering mid-stage clinical testing for viral conjunctivitis," said Ron Najafi, Ph.D., chairman and chief executive officer of NovaBay. "This is the first step in the ophthalmic clinical development program for NVC-422, which has the immediate goal o
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.; Alcon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ORBIS and Alcon Call Attention to the Aging Eye
2. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
3. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
4. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
5. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
6. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Cytopia Commences Second Phase II Study in Brain Cancer
10. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
11. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... CHAPEL HILL, N.C. , May 22, 2015 ... is critical to pharmaceutical brand recognition and success. ... Practices, LLC conducted a study to provide pharmaceutical ... level of investment (FTEs and budget) that are ... companies. Pharmaceutical and biotech marketing managers can utilize ...
(Date:5/22/2015)... , May 22, 2015 The ... in 2014 and is estimated to reach $90.7 million by ... Browse through the TOC of North America Dental ... with the help of various tables and figures. ... 10% customization on this report.   Dental ...
(Date:5/22/2015)... -- The Mesothelioma Victims Center is incredibly passionate about ... best possible compensation, and they are also extremely focused ... caused by exposure to asbestos or their family ... options such as a recent possible medical breakthrough. For ... anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
... Benefits Including Stress Reduction, Pain Relief and Improved Sleep ... According to the American Medical Association, stress is a ... The World Health Organization cites stress as America,s No. ... stress a "major health problem." An Arizona entrepreneur, however, ...
... Body mass index (BMI) should be taken into account ... researchers at Cancer Treatment Centers of America ... lower levels of vitamin D compared to non-obese patients. , ... , , The association between vitamin D and obesity ...
Cached Medicine Technology:Scottsdale Facility to Be First in U.S. to Showcase True REST Technology 2Scottsdale Facility to Be First in U.S. to Showcase True REST Technology 3Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients 2
(Date:5/22/2015)... Pasadena, Calif. (PRWEB) May 22, 2015 ... where technology, communication and capacity are intersecting to ... and across society, the opening speaker at WesternU's ... , California Lieut. Gov. Gavin Newsom, a former ... was the keynote speaker at the graduation ceremony ...
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... OH (PRWEB) May 22, 2015 River ... that Kyle Johnson, the health system’s Chief Financial Officer ... interests. Johnson has served as the company CFO since ... West will be joining the health system as CFO. ... an interim basis, while the Board of Trustees conducts ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will ... obstructive pulmonary disorder (COPD) as the dominant companies ... as well as Germany’s Boehringer Ingelheim compete with ... will market payers, clinicians and patients be disposed ... completely new ones? , In spite of recently ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... N.C., Sept. 21 Whether it is bragged or whispered about, ... recent study by Adam & Eve shows that for most folks, ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090921/LA79100 ) , , (Logo: ... the most trusted name in adult entertainment, recently asked over 1,000 ...
... ... Traumatic Brain Injury , ... September 21, 2009 -- In the current issue of Molecular Medicine, a team of scientists ... progesterone may be beneficial in protecting the brain after traumatic injury. Traumatic brain ...
... children under 10 will need two doses, preliminary U.S. trial ... who are between 10 and 17 years old will apparently ... according to initial results of ongoing trials, U.S. health officials ... two doses of the new H1N1 vaccine, the officials added. ...
... , SACRAMENTO, Calif., Sept. 21 Former California Assembly ... a Purple Ribbon Panel and Task Force starting work today to ... double among Californians by the year 2030. The state has not ... , Brown will be joined by Lloyd Dean, Jonathan ...
... ... face transplant are offering full details about the research, preparation, actual surgery and current ... ... first near-total face transplant, the surgeons involved are offering full details about the research, ...
... , FORT WASHINGTON, Pa., Sept. 21 A ... LACTAID(R) Brand found that 77 percent of Latinas reduce the amount of ... lactose intolerance. Yet, 63 percent of Latinas who have lactose intolerance ... and vitamins A and D. Despite their concerns, only 14 percent ...
Cached Medicine News:Health News:Adam & Eve's 'Great American Sex Survey' Asks 'How Was YOUR First Time?' 2Health News:News from the Latest Issue of Molecular Medicine 2Health News:1 Swine Flu Shot Enough for Older Kids 2Health News:1 Swine Flu Shot Enough for Older Kids 3Health News:Elaine Alquist, Willie Brown and Kim Belshe Convene Purple Ribbon Panel, Task Force on Alzheimer's 2Health News:Details Emerge About Approach, Results of First US Face Transplant 2Health News:New Research Finds Latinas with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 2Health News:New Research Finds Latinas with Lactose Intolerance Manage Their Condition by Limiting or Avoiding Dairy 3
Inquire...
... Pectoralis Implants come in three styles. Each ... by far the most popular style. Pectoral ... are packaged and sold individually, not in ... they are each made for a specific ...
... The latest software product in the IQmark ... new, more efficient levels of portability, cost-savings and ... is perfect for use in the office, clinics ... and emergency situations. , ,When used in conjunction ...
... EZ Holter is engineered to set a ... you do is enter the patient demographics, ... ,This three-channel, Windows based system uses the ... accuracy and versatility of the IQmark Holter ...
Medicine Products: